Opportunity for Soleno Therapeutics Investors to Lead Securities Fraud Lawsuit and Recover Losses

Soleno Therapeutics Investors Have a Chance to Lead a Class Action Lawsuit

In a significant development for investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO), the Law Offices of Howard G. Smith have announced an opportunity for shareholders who suffered substantial losses to take a leadership role in a burgeoning securities fraud class action lawsuit. This initiative is focused on addressing the financial setbacks that many investors have faced due to alleged misleading practices by the company.

Understanding the Class Action Lawsuit

The lawsuit arises from concerns related to Soleno's clinical trial program for DCCR, a treatment aimed at addressing hyperphagia in individuals with Prader-Willi Syndrome (PWS). Allegations suggest that the company failed to disclose critical safety information associated with the drug's administration. Notably, between March 26, 2025, and November 4, 2026, Soleno reportedly downplayed and misrepresented safety concerns tied to DCCR, failing to inform investors about risks such as excess fluid retention that arose during clinical trials.

Furthermore, the complaint indicates that these undisclosed issues contributed to the drug's low commercial viability, taking into account potential adverse effects post-product launch. Investors were allegedly misled by positive statements from Soleno executives about the company's business, operations, and future prospects, creating a misleading narrative that ultimately eroded investor confidence and caused significant financial damage.

Important Deadlines and Contact Information

For shareholders looking to participate in this class action, the deadline is approaching quickly. Interested investors are urged to contact the Law Offices of Howard G. Smith by May 5, 2026. This communication will help determine their eligibility to lead the lawsuit, a vital step towards recovering their losses. The firm is accessible via email at [email protected] or by phone at (215) 638-4847, and additional information is available at their website, www.howardsmithlaw.com.

Implications for Shareholders

The stakes in this lawsuit are considerable, both for the investors involved and for the future of Soleno Therapeutics. If the case proceeds, it could potentially unveil further information regarding the company's practices. Additionally, the outcome could influence future investor relations and the company’s overall credibility in the pharmaceutical market.

For those contemplating whether to join the lawsuit, it’s crucial to understand that they are not required to take immediate action. Investors have the option to seek representation or remain passive participants in the class action. By maintaining this flexibility, affected shareholders can better navigate their choices while ensuring their legal rights are considered.

Conclusion

As the May 5th deadline approaches, Soleno Therapeutics investors who have incurred losses should weigh their options carefully. Engaging in this securities fraud class action may be a vital step toward holding the company accountable and recovering losses that have impacted many shareholders. With significant allegations on the table, the outcome could herald vital changes for Soleno, investors, and its market presence in the long term.

For further inquiries about participation in this class action lawsuit, stakeholders are encouraged to reach out to the Law Offices of Howard G. Smith without delay.